221 related articles for article (PubMed ID: 9926249)
21. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua.
Baez F; Ocampo E; Conter V; Flores A; Gutierrez T; Malta A; Pacheco C; Palacios R; Biondi A; Riva L; Sala A; Silvestri D; Cavalli F; Sessa C; Casanova M; Masera G
Ann Oncol; 1997 Mar; 8(3):247-50. PubMed ID: 9137793
[TBL] [Abstract][Full Text] [Related]
22. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90.
Landman-Parker J; Pacquement H; Leblanc T; Habrand JL; Terrier-Lacombe MJ; Bertrand Y; Perel Y; Robert A; Coze C; Thuret I; Donadieu J; Schaison G; Leverger G; Lemerle J; Oberlin O
J Clin Oncol; 2000 Apr; 18(7):1500-7. PubMed ID: 10735898
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
[TBL] [Abstract][Full Text] [Related]
24. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
[TBL] [Abstract][Full Text] [Related]
25. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
Loeffler M; Diehl V; Pfreundschuh M; Rühl U; Hasenclever D; Nisters-Backes H; Sieber M; Tesch H; Franklin J; Geilen W; Bartels H; Cartoni C; Dölken G; Enzian J; Fuchs R; Gassmann W; Gerhartz H; Hagen-Aukamp U; Hiller E; Hinkelbein H; Hinterberger W; Kirchner H; Koch P; Krüger B; Schwarze EW
J Clin Oncol; 1997 Jun; 15(6):2275-87. PubMed ID: 9196141
[TBL] [Abstract][Full Text] [Related]
26. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
[TBL] [Abstract][Full Text] [Related]
27. [Significance of procarbazine in the chemotherapy of Hodgkin's disease--a report of the Cooperative Therapy Study DAL-HD-85].
Schellong G; Hörnig I; Brämswig J; Bökkerink JP; Steinhoff A; Ludwig R; Niethammer D; Reiter A; von Lengerke HJ; Heinecke H
Klin Padiatr; 1988; 200(3):205-13. PubMed ID: 3062257
[TBL] [Abstract][Full Text] [Related]
28. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
29. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
Rüffer JU; Ballova V; Glossmann J; Sieber M; Franklin J; Nogova L; Diehl V; Josting A;
Leuk Lymphoma; 2005 Nov; 46(11):1561-7. PubMed ID: 16236610
[TBL] [Abstract][Full Text] [Related]
30. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
31. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
32. [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?].
Müller J; Molnár Z; Illés A; Csóka M; Jakab Z; Deák B; Schneider T; Várady E; Rosta A; Simon Z; Keresztes K; Gergely L; Kovács G
Orv Hetil; 2008 Nov; 149(47):2221-7. PubMed ID: 19004744
[TBL] [Abstract][Full Text] [Related]
33. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
[TBL] [Abstract][Full Text] [Related]
34. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
35. Risk adapted combined modality treatment in children with Hodgkin's disease: NCI, Cairo.
El-Badawy S; Aboulnaga S; Abou Gabal A; Mokhless A; Zamzam M; Sidhom I; Ebeid E; Hussein H
J Egypt Natl Canc Inst; 2008 Jun; 20(2):99-110. PubMed ID: 20029465
[TBL] [Abstract][Full Text] [Related]
36. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.
Hunger SP; Link MP; Donaldson SS
J Clin Oncol; 1994 Oct; 12(10):2160-6. PubMed ID: 7523608
[TBL] [Abstract][Full Text] [Related]
37. Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina.
Sackmann-Muriel F; Zubizarreta P; Gallo G; Scopinaro M; Alderete D; Alfaro E; Casak S; Chantada G; Felice MS; Quinteros R
Med Pediatr Oncol; 1997 Dec; 29(6):544-52. PubMed ID: 9324342
[TBL] [Abstract][Full Text] [Related]
38. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
39. [Therapy studies of the German Hodgkin's Study Group. Intermediate results of the study protocols HD1, HD2, and HD3].
Diehl V; Pfreundschuh M; Löffler M; Smith K; Rühl U; Georgii A; Hiller E; Gerhartz H
Onkologie; 1987 Apr; 10(2):62-6. PubMed ID: 2438613
[TBL] [Abstract][Full Text] [Related]
40. [Reducing radiation dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study].
Schellong G; Hörnig-Franz I; Rath B; Ritter J; Riepenhausen M; Kabisch H; Goldschmitt-Wuttge B; Schmidt P; Niethammer D; Gaedicke G
Klin Padiatr; 1994; 206(4):253-62. PubMed ID: 7967421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
